gsk201208106k3.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending August 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 


 

`
 
 
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
 
Following a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan (The Plan), which is notionally held in GSK American Depositary Shares (ADSs), the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned Persons on 10 August 2012 of an increase in the notional allocation of ADSs on 9 August 2012 at a price of $46.69 per ADS:-
 
 
 
Director/PDMR
 
 
 
Number of ADSs
 
Connected Person
 
Number of ADSs
 
Dr M M Slaoui
 
 
10
 
Dr K Slaoui
 
9
Mr W C Louv
 
16
-
-
Dr D Pulman
 
28
-
-
Mr E J Gray
 
21
-
-
Mrs D P Connelly
 
1
-
-
     
           
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
 
 
V A Whyte
Company Secretary
 
10 August 2012
 
 

 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: August 10, 2012
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc